Arrowstreet Capital
CTMX icon

Arrowstreet Capital’s CytomX Therapeutics CTMX Stock Holding History

Arrowstreet Capital’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-286,039
Closed -$1.87M – 2286
2020
Q4 		$1.87M Buy
286,039
+175,693
+159% +$1.26M ﹤0.01% 1623
2020
Q3 		$734K Buy
110,346
+27,394
+33% +$203K ﹤0.01% 1903
2020
Q2 		$691K Buy
+82,952
New +$770K ﹤0.01% 1891
2018
Q4 		– Sell
-163,887
Closed -$3.03M – 1363
2018
Q3 		$3.03M Buy
163,887
+87,796
+115% +$2M 0.01% 615
2018
Q2 		$1.74M Buy
76,091
+50,268
+195% +$1.28M ﹤0.01% 707
2018
Q1 		$735K Buy
+25,823
New +$737K ﹤0.01% 912

Other funds holding CTMX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Arrowstreet Capital's CTMX Position: Q1 2021 in Review

Arrowstreet Capital sold out of CytomX Therapeutics (CTMX) in Q1 2021, closing a stake of 286,039 shares — an estimated $1.87M sold.

Arrowstreet Capital first reported a position in CTMX in Q1 2018 and held it in 6 quarters. The position peaked at $3.03M in Q3 2018. 126 funds tracked by Wall St. Rank hold CTMX as of Q1 2021.

  • Arrowstreet Capital reported no remaining CytomX Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Arrowstreet Capital sold 286,039 CytomX Therapeutics shares in Q1 2021, an estimated $1.87M.
  • Arrowstreet Capital first reported a position in CytomX Therapeutics in Q1 2018 and held it in 6 quarters.
  • Arrowstreet Capital's CytomX Therapeutics position peaked at $3.03M in Q3 2018.
  • 126 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2021.

Based on Arrowstreet Capital's 13F filing for Q1 2021, filed 14 May 2021.